OpGen, Inc. (OPGN)
| Market Cap | 51.50M |
| Revenue (ttm) | 3.68M |
| Net Income (ttm) | -21.62M |
| Shares Out | 19.12M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $2.33 |
| Previous Close | $2.29 |
| Change ($) | 0.04 |
| Change (%) | 1.75% |
| Day's Open | 2.31 |
| Day's Range | 2.27 - 2.43 |
| Day's Volume | 895,659 |
| 52-Week Range | 1.42 - 4.04 |
GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics ...
Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth
Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing
GAITHERSBURG, Md., Nov. 24, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...
Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q3 2020 Results - Earnings Call Transcript
Conference call to be held at 4:30 p.m. Eastern Time today
GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third ...
OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics ...
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...
GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...
Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Sept. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnosti...
GAITHERSBURG, Md., Sept. 18, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockho...
Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance
Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic Affairs
GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 02, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnost...
OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its subsidiary obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB detectio...
Shares of Maryland-based OpGen Inc. OPGN, -0.96% rocketed 43% in active premarket trading Thursday, after the molecular diagnostics company said its Germany-based Curetis GmbH subsidiary obtai...
- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2020 Results - Earnings Call Transcript
Shares of OpGen (NASDAQ:OPGN) rose 4.98% in after-market trading after the company reported Q2 results.
Conference call to be held at 4:30 p.m. Eastern Time today
OpGen (NASDAQ: OPGN) will be releasing its next round of earnings this Wednesday, August 12.
Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database
GAITHERSBURG, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and prom...
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its seco...
GAITHERSBURG, Md., July 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN)(“OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help c...
Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products Strategic partnership will focus on commercia...
- European Investment Bank (EIB) and OpGen, Curetis GmbH and Ares Genetics GmbH enter into Amendment to the EIB Financing Agreement
If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.
OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just fiv...
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, June 09, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostic...
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help co...
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2020 Results - Earnings Call Transcript
- Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections
Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species a...
Following strong support from shareholders, OpGen and Curetis consummated their business combination transaction
Vote approving transaction passes with 95% support for the transaction
OpGen, Inc. (OPGN) CEO Evan Jones on Q4 2019 Results - Earnings Call Transcript
Shareholder proxy vote achieves quorum with 99% support for the transaction
In an analysis of K. pneumoniae bacterial isolates, an overall agreement of 95.6% was observed between phenotypic antimicrobial susceptibility and genotypic prediction by OpGen’s Acuitas Light...
Shareholder proxy vote stands at 97% of the required quorum with support for the transaction at over 95% Shareholder proxy vote stands at 97% of the required quorum with support for the transa...
OpGen (OPGN) news for Monday includes OPGN stock taking off following an update on test kits for the coronavirus from China. The post OpGen (OPGN) Stock Skyrockets 128% on Rapid Coronavirus Te...
OpGen Inc (NASDAQ: OPGN) shares were ripping higher Monday in reaction to an announcement regarding a COVID-19 test kit from German molecular diagnostics company Curetis, which OpGen has agree...
- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours
Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018
GAITHERSBURG, Md., Feb. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help ...
OpGen Inc. (NASDAQ: OPGN) shares jumped on Thursday after the company announced that it will be joining the fight against the coronavirus (2019-nCov).
About OPGN
OpGen, a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of vari... [Read more...]
| Industry Diagnostics & Research | IPO Date May 5, 2015 |
| CEO Oliver Schacht | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol OPGN |
Financial Performance
In 2019, OpGen, Inc.'s revenue was $3.50 million, an increase of 18.75% compared to the previous year's $2.95 million. Losses were -$12.45 million, -6.89% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for OpGen, Inc. stock is "Buy." The 12-month stock price forecast is 4.83, which is an increase of 107.30% from the latest price.